B+
Bull case
25%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
OCUL
Ocular TherapeutixCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
SOL-1 met its superiority primary endpoint, and an on-schedule NDA could advance AXPAXLI toward a potential 2027 launch. Ocular reported $598.6 million in June 30 cash and expected runway into 2028, subject to its stated spending assumptions.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.1.
What can break
Kodiak's positive Phase 3 wet-AMD data and planned Q4 2026 filing could constrain AXPAXLI's differentiation and eventual uptake. Kodiak release
Momentum
5
Value
41
Sentiment
81
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $13.00 · Bear $4.00Analysis 2026-09-29; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $26.15
Why
Momentum5 · Δ7d +0.4
Value41 · Δ7d -0.1
Sentiment81 · Δ7d +8.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +8.1.
Contradictions & invalidation
- • Kodiak's positive Phase 3 wet-AMD data and planned Q4 2026 filing could constrain AXPAXLI's differentiation and eventual uptake. Kodiak release
- • Q2 2026 net revenue was approximately flat year over year at $13.5 million, while R&D expense rose to $54.1 million; the stated runway does not include full anticipated near-term commercialization costs. [#SEC-8K-2026-08-03] SEC exhibit
- • FDA acceptance of the proposed single-pivotal-trial package and the eventual label remain uncertain.
Catalyst clock
2026-10-31
Wet-AMD competitive reassessment
Lead driver: Sentiment · See AI snapshot
Momentum
5
8% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
-4.2
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
81
45% active weight
Current posture
7d trendImproving
Δ7d
+8.1
Δ21d
-2.9
Why this grade
Composite grade C. Momentum 5.5 / Value 40.6 / Sentiment 80.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-29. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.43B
Beta
0.91
Shares Out
219.62M
P/E (TTM) · Derived
-4.6
P/S (TTM)
44.11
P/FCF (TTM) · Derived
-5.44
Rev YoY
+0.1%
EPS YoY
-10.9%
Gross Margin
+87.1%
Op Margin
-603.0%
Net Debt
-$660.09M
Current Ratio
13.11
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data